These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 17252012

  • 1. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
    Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M, Brors B, Pechtel S, Bork S, Koch A, Baer A, Rohr UP, Kobbe G, von Haeseler A, Gattermann N, Haas R, Kronenwett R.
    Leukemia; 2007 Mar; 21(3):494-504. PubMed ID: 17252012
    [Abstract] [Full Text] [Related]

  • 2. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M, Maeda H, Hara H, Yamamoto Y, Furuyama J.
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [Abstract] [Full Text] [Related]

  • 3. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence.
    Bruns I, Czibere A, Fischer JC, Roels F, Cadeddu RP, Buest S, Bruennert D, Huenerlituerkoglu AN, Stoecklein NH, Singh R, Zerbini LF, Jäger M, Kobbe G, Gattermann N, Kronenwett R, Brors B, Haas R.
    Leukemia; 2009 May; 23(5):892-9. PubMed ID: 19158832
    [Abstract] [Full Text] [Related]

  • 4. Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia.
    Kronenwett R, Butterweck U, Steidl U, Kliszewski S, Neumann F, Bork S, Blanco ED, Roes N, Gräf T, Brors B, Eils R, Maercker C, Kobbe G, Gattermann N, Haas R.
    Oncogene; 2005 Aug 11; 24(34):5313-24. PubMed ID: 15806158
    [Abstract] [Full Text] [Related]

  • 5. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K, Yamaguchi H, Tarusawa M, Futaki M, Hanawa H, Tanosaki S, Dan K.
    Leukemia; 2002 Feb 11; 16(2):170-7. PubMed ID: 11840282
    [Abstract] [Full Text] [Related]

  • 6. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
    Primo D, Flores J, Quijano S, Sanchez ML, Sarasquete ME, del Pino-Montes J, Gaarder PI, Gonzalez M, Orfao A.
    Br J Haematol; 2006 Oct 11; 135(1):43-51. PubMed ID: 16939497
    [Abstract] [Full Text] [Related]

  • 7. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells.
    Salesse S, Dylla SJ, Verfaillie CM.
    Leukemia; 2004 Apr 11; 18(4):727-33. PubMed ID: 14961028
    [Abstract] [Full Text] [Related]

  • 8. Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia.
    Dvorak P, Dvorakova D, Doubek M, Faitova J, Pacholikova J, Hampl A, Mayer J.
    Leukemia; 2003 Dec 11; 17(12):2418-25. PubMed ID: 14562121
    [Abstract] [Full Text] [Related]

  • 9. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave PB.
    Blood; 1996 Jun 01; 87(11):4770-9. PubMed ID: 8639848
    [Abstract] [Full Text] [Related]

  • 10. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V.
    Blood; 1996 Oct 15; 88(8):3091-100. PubMed ID: 8874208
    [Abstract] [Full Text] [Related]

  • 11. Chronic myelogenous leukemia molecular signature.
    Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T.
    Oncogene; 2003 Jun 19; 22(25):3952-63. PubMed ID: 12813469
    [Abstract] [Full Text] [Related]

  • 12. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
    Gentil M, Hugues P, Desterke C, Telliam G, Sloma I, Souza LEB, Baykal S, Artus J, Griscelli F, Guerci A, Johnson-Ansah H, Foudi A, Bennaceur-Griscelli A, Turhan AG.
    PLoS One; 2018 Jun 19; 13(8):e0200923. PubMed ID: 30091999
    [Abstract] [Full Text] [Related]

  • 13. 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of CML patients contains BCR-ABL-negative progenitor cells.
    Jazwiec B, Mahon FX, Pigneux A, Pigeonnier V, Reiffers J.
    Exp Hematol; 1995 Dec 19; 23(14):1509-14. PubMed ID: 8542939
    [Abstract] [Full Text] [Related]

  • 14. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
    Møller GM, Frost V, Melo JV, Chantry A.
    FEBS Lett; 2007 Apr 03; 581(7):1329-34. PubMed ID: 17349636
    [Abstract] [Full Text] [Related]

  • 15. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
    Chu S, Li L, Singh H, Bhatia R.
    Cancer Res; 2007 Jul 15; 67(14):7045-53. PubMed ID: 17638918
    [Abstract] [Full Text] [Related]

  • 16. BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells.
    Jongen-Lavrencic M, Salesse S, Delwel R, Verfaillie CM.
    Leukemia; 2005 Mar 15; 19(3):373-80. PubMed ID: 15674360
    [Abstract] [Full Text] [Related]

  • 17. The growth factor independence-1 (Gfi1) is overexpressed in chronic myelogenous leukemia.
    Huang M, Hu Z, Chang W, Ou D, Zhou J, Zhang Y.
    Acta Haematol; 2010 Mar 15; 123(1):1-5. PubMed ID: 19887785
    [Abstract] [Full Text] [Related]

  • 18. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients.
    Levescot A, Flamant S, Basbous S, Jacomet F, Féraud O, Anne Bourgeois E, Bonnet ML, Giraud C, Roy L, Barra A, Chomel JC, Turhan A, Guilhot F, Girard JP, Gombert JM, Herbelin A.
    Cancer Res; 2014 May 15; 74(10):2669-76. PubMed ID: 24675360
    [Abstract] [Full Text] [Related]

  • 19. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
    Holtz MS, Forman SJ, Bhatia R.
    Leukemia; 2005 Jun 15; 19(6):1034-41. PubMed ID: 15815728
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.